Chapter 17. Antisense Agents

  1. Sotiris Missailidis
  1. Huma Khan and
  2. Sotiris Missailidis

Published Online: 7 NOV 2008

DOI: 10.1002/9780470697047.ch17

Anticancer Therapeutics

Anticancer Therapeutics

How to Cite

Khan, H. and Missailidis, S. (2008) Antisense Agents, in Anticancer Therapeutics (ed S. Missailidis), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470697047.ch17

Editor Information

  1. Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, UK

Author Information

  1. Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, UK

Publication History

  1. Published Online: 7 NOV 2008
  2. Published Print: 21 NOV 2008

ISBN Information

Print ISBN: 9780470723036

Online ISBN: 9780470697047

SEARCH

Keywords:

  • antisense oligonucleotides (ASOs);
  • human genome sequence analysis;
  • ASOs and phosphorothioate (PS)-modified backbones;
  • Ribozymes (RNA enzymes) and DNAzymes;
  • antisense therapeutic shortcomings;
  • peptide nucleic acid (PNA) antisense molecule;
  • OGX-011 (second-generation ASO);
  • antisense technology - high therapeutic potential

Summary

This chapter contains sections titled:

  • Introduction

  • Traditional Antisense Oligonucleotides (ASOs)

  • Ribozymes and DNAzymes

  • RNA Interference and siRNAs

  • Shortcomings of Antisense Therapeutics

  • Antisense Agents in Clinical Trials

  • Concluding Remarks